Perspective: VMT01/02 Melanoma Data Coming For Radiotherapeutic Proof-Of-Concept
Perspective Therapeutics, Inc. expects updated data from cohorts 1 & 2 from the phase 1/2a study, using VMT-01 for the treatment of patients with MC1R-positive metastatic melanoma, in the 2nd half of 2024. The global melanoma market is expected to grow to $13.11 billion by 2029. Clinical supply agreement made with Bristol-Myers Squibb for use of Opdivo as a checkpoint inhibitor to be combined with VMT-01 to target patients with MC1R-positive metastatic melanoma.
Perspective Therapeutics Inc (CATX) Trading 3.4% Higher on Oct 2
Shares of Perspective Therapeutics Inc (CATX, Financial) surged 3.40% in mid-day trading on Oct 2. The stock reached an intraday high of $13.10, before settling at $13.06, up from its previous close of $12.63.
Is Perspective Therapeutics, Inc. (CATX) Outperforming Other Medical Stocks This Year?
Here is how Perspective Therapeutics (CATX) and Adma Biologics (ADMA) have performed compared to their sector so far this year.
3 Outperforming Stocks Surpassing Even Nvidia This Year
Nvidia (NASDAQ: NVDA ) is having a fantastic year in the markets, up 156% in 2024. That follows a 2023 return of 239%.
Wall Street Analysts Think Perspective Therapeutics (CATX) Could Surge 80.31%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 80.3% in Perspective Therapeutics (CATX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
